Overview

An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, and potential immune response of AMG 167 following multiple subcutaneous (SC, injection under the skin) dose administrations in healthy men and postmenopausal women with low bone mineral density.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen